| Author |
Subjects (%) |
Before
KTx |
After
KTx |
Indications for KTx |
Time of
follow-up |
Adverse outcome related to MS |
| Courivaud[73]a |
337 |
|
|
Not specified |
1 yr |
More atherosclerotic events |
| MS |
|
67 (20) |
107 (32) |
|
|
|
| Elkehili[74]c |
91 |
|
|
Not specified |
6 mths |
Not studied |
| Central obesity |
|
|
46 (50) |
|
|
|
| Hypertension |
|
|
58 (64) |
|
|
|
| Abnormal TG |
|
|
44 (48) |
|
|
|
| Low HDL |
|
|
33 (36) |
|
|
|
| Hyperglycemia |
|
|
29 (32) |
|
|
|
| MS |
|
|
26 (29) |
|
|
|
| Ozdemir[75]c |
112 |
|
|
Not specified |
1 yr |
higher CVD morbidity and decreased graft function |
| MS |
|
50 (17) |
|
|
|
|
| Luan [76]b |
203 |
|
97 (48) |
|
7yrs |
reduced transplant renal function |
| MS |
|
|
98 (48) |
|
|
|
| AGM |
|
|
|
|
|
|
| Kishikawa[77]c |
94 |
|
|
Not specified |
|
Not studied |
| MS |
|
|
14 (15) |
|
1-106 mths |
|
| de Vries[78]b |
606 |
|
|
Not specified |
|
impaired renal allograft function |
| MS |
|
|
383 (63) |
|
2.6-11.4 yrs |
|
| Porrini[79]a |
230 |
|
|
|
18 mths |
chronic graft dysfunction, graft loss |
| MS |
|
87 (38) |
|
Not specified |
|
|
Legend: a: retrospective study; b: prospective study. C: not specified. TG: Triglycerides. AO: Abdominal Obesity. CVD: Cardiovascular Event, AGM: Abnormal Glucose
Metabolism.